Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | $0.8t | $981.85 | -2.3% | 766.0K |
 RVMD | Revolution Medicines, Inc. Common Stock | $30.8b | $142.37 | -2.3% | 582.6K |
 INCY | Incyte Genomics Inc | $19.5b | $94.81 | -0.5% | 262.5K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $12.8b | $228.78 | +0.0% | 160.7K |
 EXEL | Exelixis Inc | $11.4b | $49.63 | -1.0% | 715.1K |
 NUVL | Nuvalent, Inc. Class A Common Stock | $8.0b | $99.49 | -2.8% | 198.3K |
 HALO | Halozyme Therapeutics, Inc. | $7.6b | $67.29 | +0.3% | 557.1K |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.2b | $31.89 | -2.4% | 491.3K |
 CELC | Celcuity Inc. Common Stock | $5.8b | $131.51 | -4.5% | 292.3K |
 CORT | Corcept Therapeutics Inc. | $5.0b | $55.94 | -0.8% | 190.6K |
 TNGX | Tango Therapeutics, Inc. | $3.6b | $20.77 | +1.0% | 1.1M |
 ERAS | Erasca, Inc. Common Stock | $3.1b | $10.09 | -1.4% | 854.4K |
 IMNM | Immunome, Inc. | $2.7b | $20.25 | -3.0% | 420.2K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $2.6b | $39.51 | -4.4% | 135.0K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.6b | $28.00 | -0.7% | 333.1K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $2.3b | $11.94 | -2.1% | 700.7K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $2.1b | $35.12 | -5.2% | 291.8K |
 ZYME | Zymeworks Inc. | $2.1b | $24.23 | +1.3% | 285.5K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.8b | $15.96 | +0.7% | 1.2M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.7b | $8.62 | -2.0% | 367.8K |
 NUVB | Nuvation Bio Inc. | $1.6b | $4.33 | +0.3% | 1.7M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.5b | $17.97 | -1.0% | 202.2K |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $24.40 | -0.8% | 87.8K |
 BHVN | Biohaven Ltd. | $1.4b | $8.66 | -1.1% | 573.3K |
 NVCR | NovoCure Limited Ordinary Shares | $1.4b | $17.74 | +0.9% | 564.5K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.3b | $27.27 | -2.1% | 63.3K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.3b | $13.31 | -2.0% | 407.9K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.2b | $28.98 | +0.7% | 204.1K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.1b | $7.92 | -2.9% | 494.9K |
 GERN | Geron Corp | $1.0b | $1.25 | -3.5% | 4.2M |
 KURA | Kura Oncology, Inc. | $0.8b | $9.19 | -0.3% | 291.8K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $6.63 | -3.9% | 779.9K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $8.30 | -2.5% | 174.3K |
 ARVN | Arvinas, Inc | $0.7b | $8.83 | -2.8% | 367.6K |
 STRO | Sutro Biopharma, Inc. | $0.6b | $35.90 | -7.9% | 102.4K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.6b | $28.36 | -2.2% | 164.0K |
 VSTM | Verastem, Inc. | $479.6m | $4.25 | -1.5% | 516.1K |
 ADCT | ADC Therapeutics SA | $479.5m | $3.23 | -0.5% | 783.1K |
 PBYI | PUMA BIOTECHNOLOGY INC | $383.6m | $6.90 | -0.3% | 84.2K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $364.6m | $56.64 | -4.4% | 80.3K |
 DCTH | Delcath Systems Inc | $363.5m | $10.95 | -1.1% | 72.8K |
 PRLD | Prelude Therapeutics Incorporated | $355.7m | $4.36 | -2.8% | 272.9K |
 IMRX | Immuneering Corporation Class A Common Stock | $338.4m | $4.91 | -4.9% | 476.9K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $287.3m | $3.71 | -8.3% | 1.1M |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $275.8m | $2.92 | +8.9% | 407.6K |
 CCCC | C4 Therapeutics, Inc. | $268.3m | $3.25 | -8.8% | 1.0M |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $240.4m | $10.89 | -1.4% | 40.4K |
 OKUR | OnKure Therapeutics, Inc. Class A Common Stock | $214.4m | $3.14 | -0.5% | 117.5K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $194.9m | $4.43 | -5.6% | 104.5K |